Recent News

572 News Items found
Investigators at Memorial Sloan Kettering have developed a new tool that could help them advance the understanding of human embryonic stem cells.
Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director (ACD) at the National Institutes of Health.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Kenneth Offit, MD, MPH
An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
Pictured: James Allison
James P. Allison, Chair of the Immunology Program in the Sloan Kettering Institute, has been elected a member of the Institute of Medicine.
Lorenz Studer
A team of Memorial Sloan Kettering investigators has reported for the first time a novel strategy to coax human embryonic stem cells (HESCs) to develop into cells that could potentially be used to repair the musculoskeletal system, including bone, cartilage, and muscle.
Pictured: Johanna Joyce
Johanna Joyce, of the Sloan Kettering Institute's Cancer Biology and Genetics Program, has been named the first incumbent of a Geoffrey Beene Junior Faculty Chair.
Researchers led by scientists at Memorial Sloan Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.
Samuel Danishefsky
Memorial Sloan Kettering Cancer Center chemist Samuel J. Danishefsky will be honored with three major awards this spring. Dr. Danishefsky is the incumbent of a Eugene W. Kettering Chair and a member of the Molecular Pharmacology and Chemistry Program in the Sloan Kettering Institute.
Scientists at Sloan Kettering Institute have discovered that the α6ß4 integrin, one of several receptor proteins, plays a key role in signaling for the formation of new blood vessels for a tumor, a process called tumor angiogenesis. By blocking the signaling activity of the α6ß4 subunit of this integrin on vascular cells, researchers found they could slow the growth of tumors.